EXoPERT EMERALD Clinical Study
About this study
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicles (EVs) extracted from human plasma for the early detection of multiple cancers, including lung, ovarian, breast, pancreatic, and colorectal cancers.
- Condition
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer
- Tested
- EXoPred
- Sponsor
- EXoPERT
Who can join
- Age
- 45 years and older
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 5
- Minimum age: 45 years
- Study condition: Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer
- Subject aged 45 years or older with a biopsy-proven or clinically suspected primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on objective findings such as radiological, serological, endoscopic, or cytological findings, whose blood was collected prior to any systemic or definitive therapy for the cancer.
- Subjects who are willing and able to provide written informed consent.
- Subjects who are willing and able to comply with the study requirements.
Exclusion 8
- Any history of cancer diagnosed and treated within 5 years prior to the date of consent.
- Subjects with a history of previous cancer treatment via surgical resection, hormonal cancer treatment, chemotherapy, radiotherapy within the past 6 months for recent cancer diagnosis.
- Subjects who have any history of an allogeneic bone marrow, stem cell transplant, or solid organ transplant.
- Subjects who are pregnant or breastfeeding women.
- Subjects who have consented and have undergone treatment in any other cancer related clinical trials withinthe past 6 months.
- Subjects who are currently in active treatment for drug abuse.
- Subjects who have received any treatment related to lung, breast, colorectal, pancreatic, or ovarian nodules, such as hormones prior to entering the study.
- Unsuitable sample for testing due to contamination, hemolysis, etc.
Where
9 sites, 9 recruiting
Albany Stratton VA Medical Center
Albany, New York, United States
John Hopkins University
Baltimore, Maryland, United States
University of Hawaii Cancer Center
Honolulu, Hawaii, United States
Lexington VA Healthcare System
Lexington, Kentucky, United States
Tibor Rubin VA Medical Center
Long Beach, California, United States
City of Hope Duarte Cancer Center
Los Angeles, California, United States
and 3 more sites on ClinicalTrials.gov
Contact
-
Young Park
(+82) 02 923 8833 paark76@korea.ac.kr
-
Yeonho Choi
(+82) 02 923 8833 yeonhochoi@exopert.com
Potential match only. Final eligibility is determined by the study team.